sales@angenesci.com
Login | Register
logo
Structures Search
Home Sulfos Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-

CAS No.:
123663-49-0
Catalog Number:
AG000KXN
Molecular Formula:
C17H14N2O6S
Molecular Weight:
374.3679
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%(HPLC)
In Stock USA
United States
$50
- +
25mg
99%(HPLC)
In Stock USA
United States
$90
- +
250mg
99%(HPLC)
In Stock USA
United States
$405
- +
Product Description
Catalog Number:
AG000KXN
Chemical Name:
Methanesulfonamide, N-[3-(formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]-
CAS Number:
123663-49-0
Molecular Formula:
C17H14N2O6S
Molecular Weight:
374.3679
MDL Number:
MFCD00882374
IUPAC Name:
N-[7-(methanesulfonamido)-4-oxo-6-phenoxychromen-3-yl]formamide
InChI:
InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20)
InChI Key:
ANMATWQYLIFGOK-UHFFFAOYSA-N
SMILES:
O=CNc1coc2c(c1=O)cc(c(c2)NS(=O)(=O)C)Oc1ccccc1
UNII:
4IHY34Y2NV
Properties
Complexity:
665  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
374.057g/mol
Formal Charge:
0
Heavy Atom Count:
26  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
374.367g/mol
Monoisotopic Mass:
374.057g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
119A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.4  
Literature
Title Journal
Iguratimod ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis. Molecular immunology 20180101
Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. The Journal of biological chemistry 20161216
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. Journal of immunology (Baltimore, Md. : 1950) 20131115
Iguratimod: a new disease-modifying antirheumatic drug. Drugs of today (Barcelona, Spain : 1998) 20120901
Autoimmune diseases: MIF as a therapeutic target. Expert opinion on therapeutic targets 20100301
Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chinese medical journal 20080405
T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis research & therapy 20080101
[Disease modifying anti-rheumatic drugs (DMARDs): an overview]. Nihon rinsho. Japanese journal of clinical medicine 20050101
A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochemical and biophysical research communications 20021220
An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20020401
Properties